Publications

Thommen B.T, Dziekan J.M, Achcar F, Tjia S, Passecker A, Buczak K, Gumpp C, Schmidt A, Rottmann M, Grüring C, Marti M, Bozdech Z, Brancucci N.M.B. Genetic validation of PfFKBP35 as an antimalarial drug target. eLife. 2023;12(RP86975). DOI: 10.7554/eLife.86975

Radohery G.F.R, Walz A, Gumpp C, Cherkaoui-Rbati M.H, Gobeau N, Gower J, Davenport M.P, Rottmann M, McCarthy J.S, Möhrle J.J, Rebelo M, Demarta-Gatsi C, Khoury D.S. Parasite viability as a measure of in vivo drug activity in preclinical and early clinical antimalarial drug assessment. Antimicrob Agents Chemother. 2022;66(7):e0011422. DOI: 10.1128/aac.00114-22

Wicha S.G, Walz A, Cherkaoui-Rbati M.H, Bundgaard N, Kuritz K, Gumpp C, Gobeau N, Möhrle J, Rottmann M, Demarta-Gatsi C. New in vitro interaction-parasite reduction ratio assay for early derisk in clinical development of antimalarial combinations. Antimicrob Agents Chemother. 2022;66(11):e0055622. DOI: 10.1128/aac.00556-22

Rottmann M, Jonat B, Gumpp C, Dhingra S.K, Giddins M.J, Yin X, Badolo L, Greco B, Fidock D.A, Oeuvray C, Spangenberg T. Preclinical antimalarial combination study of M5717, a Plasmodium falciparum elongation factor 2 inhibitor, and pyronaridine, a hemozoin formation inhibitor. Antimicrob Agents Chemother. 2020;64(4):e02181-19. DOI: 10.1128/AAC.02181-19